ClinicalTrials.gg
CompletedNCT02416271FACTUpdated Apr 14, 2015

The Forteo Alendronate Comparator Trial

A Phase 4 interventional study of Teriparatide and Alendronate in Osteoporosis, sponsored by Eli Lilly and Company. Completed at 20 sites in 4 countries. Open to female participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-04-14.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies testing teriparatide in Osteoporosis — 3 open to participants now, 5 under way, none of them phase 3. Teriparatide · Osteoporosis.

Enrollment
8th of 62
203 · median 63
Started
2001
the only one that year
Phase 4
17 of 62
2 open now
Registered
50th of 62
by date
Lead sponsor
16 of 62
Eli Lilly and Company

Among the 62 studies testing teriparatide in Osteoporosis, this one is the 8th largest by enrollment, is the only one that started in 2001, is one of 17 in phase 4, and was the 50th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

3 of the 62 studies testing teriparatide in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About teriparatide

Teriparatide: first FDA approval 2002 (FORTEO), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 45 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies testing teriparatide in Osteoporosis, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with osteoporosis.
  • Ambulatory, 5 years or more past menopause.
  • BMD T score between -2.5 and -4.0 at the lumbar spine or femoral neck.
  • Normal or clinically insignificant abnormal laboratory values, including serum calcium, parathyroid hormone (PTH) 1-84, 25-hydroxyvitamin D, and alkaline phosphatase.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with PTH or a PTH analogue.
  • Treatment with bisphosphonates within 12 months, anabolic corticosteroids or calcitriol or vitamin D analogues or agonists within 6 months, estrogens or selective estrogen receptor modulators within 3 months, or calcitonin within 2 months; therapeutic doses of fluoride; systemic use within 1 month or for more than 30 days in the prior year; use of anticoagulants within 1 month.
  • History of diseases other than osteoporosis that affect bone metabolism.
  • History of an increased risk of osteosarcoma (ie, patients with Paget disease of bone, previous skeletal exposure to external beam radiotherapy, or previous malignant neoplasm involving the skeleton).
  • Malignant neoplasms within 5 years; carcinoma in situ of the uterine cervix within 1 year.
  • Nephrolithiasis or urolithiasis within 2 years, or impaired renal function.
  • Abnormal uncorrected thyroid function.
  • Liver disease or clinical jaundice.
  • Alcohol or other drug abuse.
  • Poor medical or psychiatric risk for treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Teriparatide

    20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.

    Drug: Teriparatide · Dietary Supplement: Calcium · Dietary Supplement: Vitamin D · Drug: Placebo-Oral

  • Active comparator
    Alendronate

    10 milligrams/day alendronate orally plus SC injection placebo for 18 months.

    Drug: Alendronate · Dietary Supplement: Calcium · Dietary Supplement: Vitamin D · Drug: Placebo-SC

Interventions

  • Administered SC

    Also known as: LY333334, Forteo, Forsteo

  • Administered orally

  • Dietary supplementCalcium

    Administered orally

  • Dietary supplementVitamin D

    Administered orally

  • DrugPlacebo-Oral

    Administered orally

  • DrugPlacebo-SC

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline to 18 Months in Lumbar Spine BMD

    Time frame: Baseline, 18 Months

Secondary outcomes

  1. Percent Change from Baseline in Lumbar Spine BMD

    Time frame: Baseline, 3 Months, 6 Months, 12 Months

  2. Percent Change from Baseline in Total Hip and Femoral Neck BMD

    Time frame: Baseline, 12 Months, 18 Months

  3. Percent Change from Baseline in Trabecular Volumetric BMD at the Lumbar Spine

    Time frame: Baseline, 6 Months, 18 Months

  4. Percent Change from Baseline in Cortical BMD at the Femoral Neck

    Time frame: Baseline, 6 Months, 18 Months

  5. Percent Change from Baseline in Trabecular BMD at the Femoral Neck

    Time frame: Baseline, 6 Months, 18 Months

  6. Percent Change from Baseline in Biochemical Marker -Serum Procollagen I C-Terminal Propeptide (PICP)

    Time frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months

  7. Percent Change from Baseline in Biochemical Marker -Serum Procollagen I N-Terminal Propeptide (PINP)

    Time frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months

  8. Percent Change from Baseline in Biochemical Marker -Bone-Specific Alkaline Phosphatase (BSAP)

    Time frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months

  9. Percent Change from Baseline in Biochemical Marker -Urinary N-Telopeptide (NTX)

    Time frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months

  10. Percentage of Participants with Nonvertebral Fractures

    Time frame: 18 Months

  11. Percentage of Participants with Clinical Fractures

    Time frame: 18 Months

  12. Change from Baseline on the Back Pain Questionnaire

    Time frame: Baseline, 3 Months, 6 Months, 18 Months

07

Study locations

20 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mobile, Alabama 36693, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tustin, California 92780, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lakewood, Colorado 80227, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96814, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Illinois 62704, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46260, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Boylston, Massachusetts 01583, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arden Hills, Minnesota 55126, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63110, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morristown, New Jersey 07960, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenville, North Carolina 27834, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portland, Oregon 97213, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pittsburg, Pennsylvania 15213, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Providence, Rhode Island 02903, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Recife, 52051, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sao Paulo, 040024, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 14000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mezzanine, 06100, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00935, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001, a primary completion of May 2003 and a completion of May 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2015
First posted
Apr 14, 2015
Start
Apr 2001
Primary completionActual
May 2003
CompletionActual
May 2003
Last update
Apr 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02416271
Responsible party
Sponsor
First posted
Apr 14, 2015
Start date
Apr 2001
Primary completion
May 2003
Completion
May 2003
Last update
Apr 14, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teriparatide

Start the discussion